Skip to content
RNAimmune logo — Novel medicine for all through mRNA therapeutics.

RNAimmune

Novel medicine for all through mRNA therapeutics.

Founded 2020 United States Gaithersburg, United States 9 employees Series A Total: $39.35M Biotechnology, Health Care +1

General Information

Company Name RNAimmune
Founded Year 2020
Location United States Gaithersburg, United States
Employees 9
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with RNAimmune. To contact RNAimmune, visit rnaimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RNAimmune compare?

A PDF of RNAimmune and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RNAimmune soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RNAimmune

RNAimmune is a burgeoning player in the Biotechnology, Health Care, and Life Sciences industries, founded in 2020 with its headquarters in the United States. The company has established a compelling mission of delivering "Novel medicine for all through mRNA therapeutics." By leveraging cutting-edge mRNA technology, RNAimmune focuses on developing vaccines targeting cancer and respiratory viruses, highlighting its expertise in antigen engineering, targeted delivery, and novel lipid research.

In a significant stride towards growth, RNAimmune secured a $27.00M Series A investment on 29 March 2022. Key investors in this round include the Rotating Boulder Fund, Sirnaomics, and Smooth River, reflecting strong confidence from experienced stakeholders. As a young but ambitious enterprise, RNAimmune's collaborative approach positions it to revolutionize health care and address unmet medical needs on a global scale.

Services & Products

Development of mRNA-based vaccines
Cancer therapies
Antibody therapies
Treatment of rare diseases
Prophylactic vaccines
mRNA cancer immunotherapies
Research and development in mRNA design and delivery

Target Customers

Healthcare providers Pharmaceutical companies Biotech research institutions Regulatory bodies Patients in need of cancer and rare disease therapies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $27.00M 2
Rotating Boulder Fund, Sirnaomics
01 Mar 2022
Seed $10.00M 6
Terra Magnum Capital Partners, Sirnaomics +4
01 Apr 2021
Seed $2.35M 1
Terra Magnum Capital Partners
01 Aug 2020

RNAimmune Alternatives & Competitors

View All Alternatives
RNAimmune vs
Neogene Therapeutics
Neogene Therapeutics The Netherlands

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid ca...

Acquired
45 employees
Biotechnology, Health Care
RNAimmune vs

Modulating DNA damage responses to cure cancer

Venture round
3 employees
Biotechnology, Health Care
RNAimmune vs
ExcepGen
ExcepGen United States

Solving fundamental problems in drug discovery to create a new generation of therapeutics.

Seed
3 employees
Biopharma, Biotechnology

FAQ About RNAimmune

Novel medicine for all through mRNA therapeutics.
RNAimmune was founded in 2020.
RNAimmune is headquartered in Gaithersburg, United States.
RNAimmune operates in Biotechnology, Health Care and Life Sciences. Its customers include Healthcare providers, Pharmaceutical companies and Biotech research institutions.
RNAimmune has approximately 9 employees.
RNAimmune has completed 3 funding rounds, raising a total of $39.35M. The latest funding stage is Series A.
RNAimmune offers: Development of mRNA-based vaccines, Cancer therapies, Antibody therapies, Treatment of rare diseases, Prophylactic vaccines, mRNA cancer immunotherapies, Research and development in mRNA design and delivery.
Top alternatives and competitors to RNAimmune include Neogene Therapeutics, Breakpoint Therapeutics, ExcepGen, RayzeBio, SmartCella Holding AB. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RNAimmune and Neogene Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RNAimmune, https://www.bouncewatch.com/company/rnaimmune, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout